3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Ovarian Neoplasms
2
Urinary Bladder Neoplasms
1
Stomach Neoplasms
1
Melanoma
1
Lymphoma, Follicular
1
Lymphoma
1
Fallopian Tube Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Renal Cell
1
Carcinoma, Ovarian Epithelial
1
Breast Neoplasms
1
Adenoviridae Infections
1
Interventions
Cyclophosphamide
26
Rituximab
22
Biopsy
17
Specimen Handling
16
Prednisone
15
Magnetic Resonance Spectroscopy
14
Doxorubicin
14
fludarabine
12
Vincristine
12
fludarabine phosphate
9
Etoposide
7
Bendamustine Hydrochloride
7
Tacrolimus
6
Nuclear Medicine Department, Hospital
6
Melphalan
6
trametinib
5
acalabrutinib
5
X-Rays
5
Whole-Body Irradiation
5
Radiotherapy
5
Mycophenolic Acid
5
Lenalidomide
5
Crizotinib
5
pembrolizumab
4
ibrutinib
4
copanlisib
4
Prednisolone
4
Mesna
4
Dexamethasone
4
Cytarabine
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma
×
1-dodecylpyridoxal
×
Clear all
NCT06425302
2026-01-08
GOLSEEK-2
Celgene
Phase 2
Active not recruiting
90 enrolled